

**Repurposing drugs against main protease of SARS-CoV-2: mechanism based insights supported
by available laboratory and clinical data**

Sohini Chakraborti, Sneha Bheemireddy, Narayanaswamy Srinivasan*

Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560012, India




**Corresponding author*

E-mail: ns@iisc.ac.in


Supplementary Information:

- I. 2D chemical structures of molecules considered for docking in workflow-I (the images of the structures have been generated using Maestro GUI (Schrödinger, LLC) freely available for academic usage).
- II. 2D chemical structures of molecules considered for docking in workflow-II (the images of the structures have been generated using Maestro GUI (Schrödinger, LLC) freely available for academic usage).
- III. List of references to support anti-viral and/specifically anti-coronavirus property of indicated molecules in Table S4.

I. 2D chemical structures of molecules considered for docking in workflow-I


Sl. No.	Chemical structure	Name of the molecule
1	 <chem>NC(=N)NC(=O)c1nc(Cl)c(N)c(N)n1</chem>	Amiloride
2	 <chem>NC(CCCCC)C(=O)O</chem>	Aminocaproic acid
3	 <chem>COc1ccc(cc1)n2nc3c(nc23)C(=O)N4CCN(C4c5ccc(cc5)N6CCN(C6)C(=O)N7CCCCC7)C8=CC=CC=C8</chem>	Apixaban

4




Argatroban

5




Asunapreir

6




Betrixaban

7




Camostat

8




Ciluprevir

9




Dabigatran

10




Danoprevir

11




Dexibuprofen

12




Edoxaban

13




Foretinib

14




Freselestat

15




Gabexate

16




Glecaprevir

17




Ibuprofen

18




Iloprost

19




Nafamostat

20




Nesbuvir

21




Remdesivir

22




Ribavirin

23







Simeprevir

24




Tranexamic acid

II. 2D chemical structures of molecules considered for docking in workflow-II


Sl. No.	Chemical structure	Name of the molecule
1	 <p>The chemical structure of Beclabuvir is a complex molecule featuring a central benzimidazole ring system. It is substituted with a cyclohexane ring, a methylsulfonyl group, a hydroxyl group, and a piperidine ring. The piperidine ring is further substituted with a methyl group and a methoxy group.</p>	Beclabuvir
2	 <p>The chemical structure of Bictegravir consists of a central pyridine ring substituted with a hydroxyl group and a carbonyl group. This pyridine ring is linked via a methylene group to a secondary amine, which is further substituted with a 2,4,6-trifluorophenyl group.</p>	Bictegravir
3	 <p>The chemical structure of Bromocriptine features a complex polycyclic system. It includes a brominated indole ring, a piperidine ring, and a pyrrolidine ring, all interconnected through various amide and ether linkages.</p>	Bromocriptine
4	 <p>The chemical structure of Ceftolozane is a complex molecule with a central beta-lactam ring system. It is substituted with a thiazolidine ring, a sulfonamide group, and a piperazine ring. The piperazine ring is further substituted with a methyl group and a propylamine group.</p>	Ceftolozane

5




Ergotamine

6




Nikkomycin Z

7




Oxytetracycline

8




Rifabutin

9




Tigecycline

10




UK-432,097

11




Vinblastine

12




Vincristine

13




Vindesine

14




Vinflunine

15



Vinorelbine

16



Zoliflodacin

III. List of references to support anti-viral and/specifically anti-coronavirus property of indicated molecules in Table S4.

Sl. No. as per table S4	Drug_Name ^[Ref.]
1	Benzyl (2-oxopropyl)carbamate ¹
2	2-[(2,4-dichloro-5-methylphenyl)sulfonyl]-1,3-dinitro-5-(trifluoromethyl)benzene ²
3	S-[5-(trifluoromethyl)-4h-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate ²
4	5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide ³
5	Nalpha-[(benzyloxy)carbonyl]-n-[(1r)-4-hydroxy-1-methyl-2-oxobutyl]-l-phenylalaninamide ⁴
6	4-(Dimethylamino)benzoic acid ⁵
8	Ethyl (4R)-4- {[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5- {[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate ⁶⁻⁸
9	Phenylalanine boronic acid ⁹⁻¹¹
29	{1-[2-(1-formyl-propyl)-3-methanesulfonylamino-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid tert-butyl ester ¹²
30	Nesbuvir ¹³
31	Asunaprevir ¹⁴
32	(2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid ¹⁵
33	Ciluprevir ¹⁶
34	Danoprevir ¹⁷
35	N-[(2R,3S)-1-((2S)-2- {[(cyclopentylamino)carbonyl]amino}-3-methylbutanoyl)-2-(1-formyl-1-cyclobutyl)pyrrolidinyl]cyclopropanecarboxamide ¹⁸
36	Simeprevir ¹⁹
37	Glecaprevir ²⁰
38	(3R)-3-[3,5-Bis(trifluoromethyl)anilino]-2-cyano-3-sulfanylpropanamide ²¹
39	2- {[N-(2-acetyl-5-chloro-4-fluorophenyl)glycyl]amino} benzoic acid ²²
40	2- {[(4-chlorophenoxy)acetyl]amino} benzoic acid ²²
41	1-[(2-amino-4-chloro-5-methylphenyl)sulfonyl]-l-proline ²³
42	3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one ²⁴
43	5-(4-cyanophenyl)-3- {[(2-methylphenyl)sulfonyl]amino} thiophene-2-carboxylic acid ²⁵
44	5-(4-fluorophenyl)-3- {[(4-methylphenyl)sulfonyl]amino} thiophene-2-carboxylic acid ²⁵
45	5'-acetyl-4- {[(2,4-dimethylphenyl)sulfonyl]amino}-2,2'-bithiophene-5-carboxylic acid ²⁵
71	N-Benzyloxycarbonyl-l-serine-betalactone ^{26,27}
72	Phenylalanylamide ²⁶
113	Bictgravir ^{28,29}
129	Ruzasvir ³⁰
132	Setrobuvir ³¹

136	Beclabuvir ³²
148	GS-9256 ³³

References:

- 1 U. Bacha, J. Barrila, S. B. Gabelli, Y. Kiso, L. Mario Amzel and E. Freire, *Chem. Biol. Drug Des.*, 2008, **72**, 34–49.
- 2 I.-L. Lu, N. Mahindroo, P.-H. Liang, Y.-H. Peng, C.-J. Kuo, K.-C. Tsai, H.-P. Hsieh, Y.-S. Chao and S.-Y. Wu, *J. Med. Chem.*, 2006, **49**, 5154–5161.
- 3 A. D. Mesecar, K. Ratia and S. Pegan, A new class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
- 4 D. H. Goetz, Y. Choe, E. Hansell, Y. T. Chen, M. McDowell, C. B. Jonsson, W. R. Roush, J. McKerrow and C. S. Craik, *Biochemistry*, 2007, **46**, 8744–8752.
- 5 K. H. G. Verschuere, K. Pumpor, S. Anemüller, S. Chen, J. R. Mesters and R. Hilgenfeld, *Chem. Biol.*, 2008, **15**, 597–606.
- 6 S. Yuan, K. Fan, Z. Chen, Y. Sun, H. Hou and L. Zhu, *Viro. Sin.*, , DOI:10.1007/s12250-020-00196-4.
- 7 J. Wang, T. Fan, X. Yao, Z. Wu, L. Guo, X. Lei, J. Wang, M. Wang, Q. Jin and S. Cui, *J. Virol.*, 2011, **85**, 10021–10030.
- 8 D. A. Matthews, P. S. Dragovich, S. E. Webber, S. A. Fuhrman, A. K. Patick, L. S. Zalman, T. F. Hendrickson, R. A. Love, T. J. Prins, J. T. Marakovits, R. Zhou, J. Tikhe, C. E. Ford, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, M. A. Brothers, D. M. DeLisle and S. T. Worland, *Proc. Natl. Acad. Sci.*, 1999, **96**, 11000–11007.
- 9 R. Bone, D. Frank, C. A. Kettner and D. A. Agard, *Biochemistry*, 1989, **28**, 7600–7609.
- 10 R. Bone, A. Fujishige, C. A. Kettner and D. A. Agard, *Biochemistry*, 1991, **30**, 10388–10398.
- 11 J. E. Mace and D. A. Agard, *J. Mol. Biol.*, 1995, **254**, 720–736.
- 12 D. M. Andrews, H. Chaignot, B. A. Coomber, A. C. Good, S. L. Hind, M. R. Johnson, P. S. Jones, G. Mills, J. E. Robinson, T. Skarzynski, M. J. Slater and D. O. Somers, *Org. Lett.*, 2002, **4**, 4479–4482.
- 13 J. Q. Hang, Y. Yang, S. F. Harris, V. Leveque, H. J. Whittington, S. Rajyaguru, G. Ao-Ieong, M. F. McCown, A. Wong, A. M. Giannetti, S. Le Pogam, F. Talamás, N. Cammack, I. Nájera and K. Klumpp, *J. Biol. Chem.* , 2009, **284**, 15517–15529.
- 14 I. Gentile, A. R. Buonomo, E. Zappulo, G. Minei, F. Morisco, F. Borrelli, N. Coppola and G. Borgia, *Ther Clin Risk Manag.*, 2014, **10**, 493–504.
- 15 J. A. Pfefferkorn, M. L. Greene, R. A. Nugent, R. J. Gross, M. A. Mitchell, B. C. Finzel, M. S. Harris, P. A. Wells, J. A. Shelly, R. A. Anstadt, R. E. Kilkuskie, L. A. Kopta and F. J. Schwende, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2481–2486.
- 16 T. Vanwolleghem, P. Meuleman, L. Libbrecht, T. Roskams, R. De Vos and G. Leroux-Roels, *Gastroenterology*, 2007, **133**, 1144–1155.
- 17 Y. He, M. S. King, D. J. Kempf, L. Lu, H. Ben Lim, P. Krishnan, W. Kati, T. Middleton and A. Molla, *Antimicrob. Agents Chemother.*, 2008, **52**, 1101 LP – 1110.

- 18 M. J. Slater, E. M. Amphlett, D. M. Andrews, P. Bamborough, S. J. Carey, M. R. Johnson, P. S. Jones, G. Mills, N. R. Parry, A. J. Stewart and T. Skarzynski, *Org. Lett.*, 2003, **5**, 4627–4630.
- 19 P. Raboisson, H. de Kock, Å. Rosenquist, M. Nilsson, L. Salvador-Oden, T.-I. Lin, N. Roue, V. Ivanov, H. Wähling, K. Wickström, E. Hamelink, M. Edlund, L. Vrang, S. Vendeville, W. Van de Vreken, D. McGowan, A. Tahri, L. Hu, C. Boutton, O. Lenz, F. Delouvroy, G. Pille, D. Surleraux, P. Wigerinck, B. Samuelsson and K. Simmen, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 4853–4858.
- 20 K. A. Salam and N. Akimitsu, *Biomed Res. Int.*, 2013, **2013**, 467869.
- 21 S. Yan, T. Appleby, E. Gunic, J. H. Shim, T. Tasu, H. Kim, F. Rong, H. Chen, R. Hamatake, J. Z. Wu, Z. Hong and N. Yao, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 28–33.
- 22 T. Nittoli, K. Curran, S. Insaf, M. DiGrandi, M. Orłowski, R. Chopra, A. Agarwal, A. Y. M. Howe, A. Prashad, M. B. Floyd, B. Johnson, A. Sutherland, K. Wheless, B. Feld, J. O’Connell, T. S. Mansour and J. Bloom, *J. Med. Chem.*, 2007, **50**, 2108–2116.
- 23 A. Gopalsamy, R. Chopra, K. Lim, G. Ciszewski, M. Shi, K. J. Curran, S. F. Sukits, K. Svenson, J. Bard, J. W. Ellingboe, A. Agarwal, G. Krishnamurthy, A. Y. M. Howe, M. Orłowski, B. Feld, J. O’Connell and T. S. Mansour, *J. Med. Chem.*, 2006, **49**, 3052–3055.
- 24 R. Tedesco, A. N. Shaw, R. Bambal, D. Chai, N. O. Concha, M. G. Darcy, D. Dhanak, D. M. Fitch, A. Gates, W. G. Gerhardt, D. L. Halegoua, C. Han, G. A. Hofmann, V. K. Johnston, A. C. Kaura, N. Liu, R. M. Keenan, J. Lin-Goerke, R. T. Sarisky, K. J. Wiggall, M. N. Zimmerman and K. J. Duffy, *J. Med. Chem.*, 2006, **49**, 971–983.
- 25 B. K. Biswal, M. Wang, M. M. Cherney, L. Chan, C. G. Yannopoulos, D. Bilimoria, J. Bedard and M. N. G. James, *J. Mol. Biol.*, 2006, **361**, 33–45.
- 26 J. Yin, E. M. Bergmann, M. M. Cherney, M. S. Lall, R. P. Jain, J. C. Vederas and M. N. G. James, *J. Mol. Biol.*, 2005, **354**, 854–871.
- 27 J. Yin, M. M. Cherney, E. M. Bergmann, J. Zhang, C. Huitema, H. Pettersson, L. D. Eltis, J. C. Vederas and M. N. G. James, *J. Mol. Biol.*, 2006, **361**, 673–686.
- 28 D. O. Passos, M. Li, I. K. Jóźwik, X. Z. Zhao, D. Santos-Martins, R. Yang, S. J. Smith, Y. Jeon, S. Forli, S. H. Hughes, T. R. Burke, R. Craigie and D. Lyumkis, *Science (80-.)*, , DOI:10.1126/science.aay8015.
- 29 N. J. Cook, W. Li, D. Berta, M. Badaoui, A. Ballandras-Colas, A. Nans, A. Kotecha, E. Rosta, A. N. Engelman and P. Cherepanov, *Science (80-.)*, 2020, **367**, 806–810.
- 30 H. Fathi, A. Clark, N. R. Hill and G. Dusheiko, *BMC Infect. Dis.*, 2017, **17**, 722.
- 31 A. S. Mayhoub, *Bioorg. Med. Chem.*, 2012, **20**, 3150–3161.
- 32 R. G. Gentles, M. Ding, J. A. Bender, C. P. Bergstrom, K. Grant-Young, P. Hewawasam, T. Hudyma, S. Martin, A. Nickel, A. Regueiro-Ren, Y. Tu, Z. Yang, K.-S. Yeung, X. Zheng, S. Chao, J.-H. Sun, B. R. Beno, D. M. Camac, C.-H. Chang, M. Gao, P. E. Morin, S. Sheriff, J. Tredup, J. Wan, M. R. Witmer, D. Xie, U. Hanumegowda, J. Knipe, K. Mosure, K. S. Santone, D. D. Parker, X. Zhuo, J. Lemm, M. Liu, L. Pelosi, K. Rigat, S. Voss, Y. Wang, Y.-K. Wang, R. J. Colonna, M. Gao, S. B. Roberts, Q. Gao, A. Ng, N. A. Meanwell and J. F. Kadow, *J. Med. Chem.*, 2014, **57**, 1855–1879.
- 33 X. C. Sheng, A. Casarez, R. Cai, M. O. Clarke, X. Chen, A. Cho, W. E. Delaney, E. Doerffler, M. Ji, M. Mertzman, R. Pakdaman, H.-J. Pyun, T. Rowe, Q. Wu, J. Xu and C. U. Kim, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 1394–1396.